Meyka Pro banner
Novo Nordisk A/S

Novo Nordisk A/S (NVO) Stock Overview

Explore Novo Nordisk A/S’s financial performance, market position, analyst ratings, and future outlook.

NVOā—NYSE
HealthcareDrug Manufacturers - General
$49.38
$0.23(0.46%)
U.S. Market opens in 15h 48m

Novo Nordisk A/S (NVO)

Meyka AI Score

Z

Key Financials

Market Cap219.4B
P/E Ratio11.84
EPS (TTM)$4.03
ROE0.66%
Fundamental Analysis

AI Price Forecasts

1 Month$28.39
3 Months$41.38
1 Year Target$3.43

NVO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Novo Nordisk A/S (NVO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 56.83, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $3.43.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 11.84 and a market capitalization of 219.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.48%
5-Day Change
-3.02%
1-Month Change
7.61%
3-Month Change
25.24%
6-Month Change
-16.77%
Year-to-Date (YTD) Change
-2.97%
1-Year Change
-23.95%
3-Year Change
-40.40%
5-Year Change
11.17%
All-Time (Max) Change
30756.25%

Contact Information

45 44 44 88 88
Novo Alle 1, Bagsvaerd, CR, 2880

Company Facts

774,060 Employees
IPO DateApr 30, 1981
CountryDK
Actively Trading

Frequently Asked Questions